Qiagen NV (QGEN) was Upgraded by HSBC Securities to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. HSBC Securities advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on Qiagen NV. Company shares were Reiterated by Mizuho on Aug 1, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .
On the company’s financial health, Qiagen NV reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.22. The company had revenue of $334.40 million for the quarter, compared to analysts expectations of $326.41 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Qiagen NV opened for trading at $25.38 and hit $27.135 on the upside on Friday, eventually ending the session at $26.8, with a gain of 14.38% or 3.37 points. The heightened volatility saw the trading volume jump to 43,46,493 shares. Company has a market cap of $6,255 M.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products as well as instruments that automate the use of these products for sample preparation analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data enabling scientists or clinicians to interpret results and decide on further action.